Occurrence of the JAK2 V617F mutation in the Buddg-Chiari syndrome

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 459-462

  Colaizzo, Donatella ^a   Amitrano, Lucio ^c   Tiscia, Giovanni L ^a   Iannaccone, Luigi ^b   Gallone, Anna ^d   Grandone, Elvira ^a   Guardascione, Maria A ^c   Margaglione, Maurizio ^a,e  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Division of Hematology   (Italy)

^c A Cardarelli Hospital   (Italy)

^d Applied Biology   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

Author keywords

AK2 V617F mutation; BuddChiari syndrome; Myeloproliferative disease; Thrombosis

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; BUDD-CHIARI SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS;

EID: 59949094293     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283049662     Document Type: Article

References (20)

1. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38:364-371.
2. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350:578-585.
3. Manten B, Westendorp RGJ, Koster T, Reitsma PH, Rosendaal FR. Risk factors profiles in patients with different clinical manifestations of venous thromboembolism. Thromb Haemost 1996; 76:510-513.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-1148.
5. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106:3374-3376.
6. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106:3377-3379.
7. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397.
8. Patel RK, Lea NC, Heneghan MA, Westwood NG, Milojkovic D, Thanigaikumar M, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031-2038.
9. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91:1712-1713.
10. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5:55-61.
11. Pierre R, Lea NC, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein H, Vardman JW, editors. The World Health Organization classification of tumors. Lyon: IARC Press; 2001. pp.32-44.
12. Chait Y, Condat B, Cazals-Hatem D, Sai Atmani PR, Chaoui D, Guilmin F, et al. Relevance of the criteria commonly used to dianose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129:553-560.
13. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnigenic myeloid metaplasia). Int J Hematol 2002; 76:133-145.
14. 20210 gene variant. Ann Intern Med 1998; 129:89-93.
15. Koeleman BPC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-1035.
16. Poort SR, Rosendal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
17. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al., United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366:1945- 1953.
18. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100:4272-4290.
19. Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117:796-808.
20. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528- 1534.